ASH 2016: Study Shows Patients Traditionally Ineligible for Studies May Benefit From Trial Participation

Key Points

  • Sixty-day survival was 83%, with low-grade gastrointestinal side effects reported.
  • The study was expanded to include an additional 79 patients. Sixty-day survival for the second group was 79%, with a median overall survival of 7.6 months.
  • The average event-free survival was 4.5 months.

Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses. A novel study at The University of Texas MD Anderson Cancer Center revealed some patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who traditionally could not be considered for clinical trials responded well and were safely treated in this setting.

The study, led by Guillermo Garcia-Manero, MD, Professor of Leukemia at MD Anderson, followed 109 patients with AML and MDS undergoing treatment with azacitidine and vorinostat (Zolinza). Research results were presented by Daver et al at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego (Abstract 763).

“Most cancer clinical studies exclude patients with comorbidities, active or recent malignancies, organ dysfunction, or poor performance status,” said Dr. Garcia-Manero. “How these criteria protect patients is unclear. Although some are based on clinical reasoning, it seems these criteria are in place more to protect the drug or intervention being studied rather than the patient.”

Study Findings

The study initially enrolled 30 patients age 17 and older who had not previously been treated for AML or MDS. Patients eligible for the study had either poor performance status, poor renal or hepatic function, or any other active systemic disorder such as another cancer. 

Sixty-day survival was 83%, with low-grade gastrointestinal side effects reported. The study was expanded to include an additional 79 patients. Sixty-day survival for the second group was 79% with a median overall survival of 7.6 months. The average event-free survival was 4.5 months. Again, only low-grade gastrointestinal side effects were observed.

The study was designed with “stopping rules” that included monitoring of side effects and complete response rates. Patients were immediately placed on another therapy if their assigned therapy did not indicate there would be a complete response within a 60-day period. To define the minimum expected survival and response rates that would trigger the stopping rules, researchers relied on prior data of 181 patients previously treated at MD Anderson.

“Participation in clinical trials is fundamental for the development of new therapeutic interventions,” said Guillermo Montalban-Bravo, MD, Fellow in Leukemia, a research team member. “Despite this need, only 3% to 5% of patients with cancer treated in the United States currently are enrolled in clinical trials.”

The study points to further evaluation of standard exclusion criteria, potentially increasing the pool of patients likely to benefit from therapy, with the aim of future larger clinical trials specifically treating patients with AML and MDS.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement